Avego Management
Avego Management is a private equity firm based in Alpharetta, Georgia, founded in 2015. The firm focuses on investing in companies across the healthcare spectrum, including diagnostics, medical devices and equipment, life sciences, and pharmaceuticals, and provides investment consultation for companies along with capital investment assistance within the healthcare industry.
5 past transactions
PBS Biotech
Venture Round in 2025
PBS Biotech specializes in single-use bioreactors and process development services for cell product manufacturing. Their bioreactors offer minimal per-liter volume footprints, ensuring scalability from R&D to clinical production stages. They provide efficient, cost-effective disposable systems alongside technical services to help clients overcome complex cell culture challenges.
AtomVie Global Radiopharma
Series A in 2023
AtomVie is a global Contract Development and Manufacturing Organization specializing in radiotherapeutics. It supports partners from early clinical development to commercial manufacturing, offering scientific, technical, regulatory, quality, logistics, and business expertise alongside specialized infrastructure.
PBS Biotech
Venture Round in 2023
PBS Biotech specializes in single-use bioreactors and process development services for cell product manufacturing. Their bioreactors offer minimal per-liter volume footprints, ensuring scalability from R&D to clinical production stages. They provide efficient, cost-effective disposable systems alongside technical services to help clients overcome complex cell culture challenges.
Escient Pharmaceuticals
Series C in 2022
Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.
AtomVie Global Radiopharma
Series A in 2022
AtomVie is a global Contract Development and Manufacturing Organization specializing in radiotherapeutics. It supports partners from early clinical development to commercial manufacturing, offering scientific, technical, regulatory, quality, logistics, and business expertise alongside specialized infrastructure.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.